The year in review and some predictions about next year/ Part One: Stem Cells
It’s time to look back at what happened this year, and make some predictions about next year. Part One will focus on stem cells. We started 2017 awaiting the FDA’s final guidance documents on HCT/P’s (“stem cells”). In late August, the FDA foreshadowed the guidance documents by issuing warning letters to two of most high profile (or infamous) stem cell clinics in the country. Both clinics were warned that their use of HCT/P’s were in violation of the FDA trifecta…